JP2012526848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526848A5 JP2012526848A5 JP2012511019A JP2012511019A JP2012526848A5 JP 2012526848 A5 JP2012526848 A5 JP 2012526848A5 JP 2012511019 A JP2012511019 A JP 2012511019A JP 2012511019 A JP2012511019 A JP 2012511019A JP 2012526848 A5 JP2012526848 A5 JP 2012526848A5
- Authority
- JP
- Japan
- Prior art keywords
- ranolazine
- composition
- nervous system
- central nervous
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17817009P | 2009-05-14 | 2009-05-14 | |
| US61/178,170 | 2009-05-14 | ||
| US27939509P | 2009-10-20 | 2009-10-20 | |
| US61/279,395 | 2009-10-20 | ||
| PCT/US2010/034778 WO2010132696A1 (en) | 2009-05-14 | 2010-05-13 | Ranolazine for the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526848A JP2012526848A (ja) | 2012-11-01 |
| JP2012526848A5 true JP2012526848A5 (https=) | 2013-06-27 |
Family
ID=42262042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511019A Pending JP2012526848A (ja) | 2009-05-14 | 2010-05-13 | Ｃｎｓ障害の治療のためのラノラジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100292217A1 (https=) |
| EP (1) | EP2429526A1 (https=) |
| JP (1) | JP2012526848A (https=) |
| AU (1) | AU2010248948A1 (https=) |
| CA (1) | CA2761771A1 (https=) |
| MX (1) | MX2011012140A (https=) |
| WO (1) | WO2010132696A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011530A (es) * | 2002-05-21 | 2005-08-15 | Cv Therapeutics Inc | Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes. |
| US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN113318111B (zh) * | 2021-06-21 | 2026-02-03 | 浙江大学 | Nav1.1激动剂在制备治疗自闭症的药物中的应用 |
| WO2025078664A1 (en) * | 2023-10-12 | 2025-04-17 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| ATE142497T1 (de) * | 1989-06-23 | 1996-09-15 | Syntex Inc | Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| DE69429524T2 (de) * | 1993-09-24 | 2002-08-08 | The University Of British Columbia, Vancouver | Aminocyclohexylester und ihre anwendung |
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| JP2004505886A (ja) * | 2000-02-18 | 2004-02-26 | スィーヴィー セラピューティクス インコーポレイテッド | 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤 |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| ATE397938T1 (de) * | 2000-05-19 | 2008-07-15 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp- 1 |
| WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| WO2003008411A1 (en) * | 2001-07-19 | 2003-01-30 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| MXPA04011530A (es) * | 2002-05-21 | 2005-08-15 | Cv Therapeutics Inc | Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes. |
| SG156681A1 (en) * | 2004-11-09 | 2009-11-26 | Cv Therapeutics Inc | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| CA2593593A1 (en) * | 2005-01-06 | 2006-07-13 | Cv Therapeutics, Inc. | Sustained release pharmaceutical formulations comprising ranolazine |
| EP2117550A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| US20090312340A1 (en) * | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| EP2117509A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2713521A1 (en) * | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| EP2337559A2 (en) * | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| WO2010068461A1 (en) * | 2008-11-25 | 2010-06-17 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
-
2010
- 2010-05-13 JP JP2012511019A patent/JP2012526848A/ja active Pending
- 2010-05-13 WO PCT/US2010/034778 patent/WO2010132696A1/en not_active Ceased
- 2010-05-13 US US12/779,753 patent/US20100292217A1/en not_active Abandoned
- 2010-05-13 AU AU2010248948A patent/AU2010248948A1/en not_active Abandoned
- 2010-05-13 EP EP10720094A patent/EP2429526A1/en not_active Withdrawn
- 2010-05-13 MX MX2011012140A patent/MX2011012140A/es active IP Right Grant
- 2010-05-13 CA CA2761771A patent/CA2761771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526848A5 (https=) | ||
| EP3658538B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| RU2014111478A (ru) | Лечение с использованием ацетата эсликарбазепина или эсликарбазепина | |
| JOP20210017A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| JP2021091690A (ja) | 急性骨髄性白血病（ａｍｌ）のための新規併用治療 | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2010531879A5 (https=) | ||
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| JP2014196370A5 (https=) | ||
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| KR20160004299A (ko) | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 | |
| JP2012111764A5 (https=) | ||
| JP2013518914A5 (https=) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2017531043A5 (https=) | ||
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| JP2016501219A5 (https=) | ||
| CN1794982A (zh) | 化合物用于预防药物诱导的细胞毒性的用途 | |
| Dantio et al. | Seizures in brain tumors: pathogenesis, risk factors and management | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта |